icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
PrceNczk7u3M9R8T
Listen
